» Articles » PMID: 29375401

Neurological Soft Signs in Schizophrenia: An Update on the State- Versus Trait-Perspective

Overview
Specialty Psychiatry
Date 2018 Jan 30
PMID 29375401
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neurological soft signs (NSS) represent minor neurological signs, which indicate non-specific cerebral dysfunction. In schizophrenia, their presence has been documented extensively across all stages of the disease. Until recently, NSS were considered an endophenotype or a trait phenomenon. During the past years, however, researchers report fluctuations of the NSS scores.

Aims: To further clarify the question whether NSS exhibit state or trait components or both, studies that have investigated NSS longitudinally were reviewed.

Method: Studies which have assessed NSS longitudinally in adults suffering from schizophrenia, were searched for. The time frame was January 1966 to June 2017. Studies on teenagers were excluded because of interferences between brain maturation and pathology.

Results: Twenty-nine follow-up studies were identified. They included patients during different stages of their illness and mainly used established instruments for NSS assessment. Patients with a first episode or a remitting course predominantly show a decrease of NSS over time, whereas a worsening of NSS can be found in the chronically ill. It was shown that change of NSS total scores over time is predominantly caused by motor system subscales and to a lesser extent by sensory integration scales. With respect to medication, the majority of studies agree on a relationship between medication response and improvement of NSS while the type of antipsychotic does not seem to play a major role. Moreover, where information on side-effects is given, it does not favor a strong relationship with NSS. However, NSS seem to correlate with negative and cognitive symptoms.

Conclusion: Studies manifest a conformity regarding the presence of NSS in schizophrenia patients on the one hand. On the other hand, fluctuations of NSS scores have been widely described in subgroups. Taken together results strongly support a state-trait dichotomy of NSS. Thus, the usage of NSS as an endophenotype has to be called into question.

Citing Articles

Sensori- and psychomotor abnormalities, psychopathological symptoms and functionality in schizophrenia-spectrum disorders: a network analytic approach.

Fritze S, Brandt G, Volkmer S, Daub J, Altinok D, Kubera K Schizophrenia (Heidelb). 2025; 11(1):16.

PMID: 39939637 PMC: 11821994. DOI: 10.1038/s41537-024-00547-0.


Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder.

Iftimovici A, Krebs E, Dalfin W, Legrand A, Scoriels L, Martinez G Psychol Med. 2024; :1-12.

PMID: 39402801 PMC: 11536111. DOI: 10.1017/S0033291724001776.


Clinical and Sociodemographic Correlations with Neurological Soft Signs in Hospitalized Patients with Schizophrenia: A Preliminary Longitudinal Study.

Petrescu C, Mihalache O, Vilciu C, Petrescu D, Marian G, Ciobanu C Biomedicines. 2024; 12(4).

PMID: 38672143 PMC: 11048323. DOI: 10.3390/biomedicines12040787.


Rare genetic brain disorders with overlapping neurological and psychiatric phenotypes.

Peall K, Owen M, Hall J Nat Rev Neurol. 2023; 20(1):7-21.

PMID: 38001363 DOI: 10.1038/s41582-023-00896-x.


Relating movement markers of schizophrenia to self-experience-a mixed-methods study.

Martin L, Melchert D, Knack M, Fuchs T Front Psychiatry. 2023; 14:1212508.

PMID: 37415694 PMC: 10319999. DOI: 10.3389/fpsyt.2023.1212508.


References
1.
Chen E, Shapleske J, Luque R, McKenna P, Hodges J, Calloway S . The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res. 1995; 56(2):183-204. DOI: 10.1016/0165-1781(95)02535-2. View

2.
Hyde T, Goldberg T, Egan M, Lener M, Weinberger D . Frontal release signs and cognition in people with schizophrenia, their siblings and healthy controls. Br J Psychiatry. 2007; 191:120-5. DOI: 10.1192/bjp.bp.106.026773. View

3.
Schroder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S . D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after.... Biol Psychiatry. 1998; 43(9):660-5. DOI: 10.1016/s0006-3223(97)00442-3. View

4.
Karlsson H, Bachmann S, Schroder J, McArthur J, Torrey E, Yolken R . Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A. 2001; 98(8):4634-9. PMC: 31886. DOI: 10.1073/pnas.061021998. View

5.
Mosher L, Pollin W, STABENAU J . Identical twins discordant for schizophrenia. Neurologic findings. Arch Gen Psychiatry. 1971; 24(5):422-30. DOI: 10.1001/archpsyc.1971.01750110034006. View